Directory · TW
Biotechnology Research in Taiwan
A register of firms and the professionals working at them in the Biotechnology Research sector based in Taiwan. Browse the public index, then filter or export on Kipplo.
Companies
264 on file
Genetex, Inc
As a multinational antibody manufacturer, GeneTex’s primary goal is to provide bioscience researchers with thoroughly validated reagents to accelerate their discovery. Established in 1997 in San Antonio, Texas by scientists with expertise in clinical oncology, cancer biology, and infectious disease, the company’s initial focus was breast cancer biology and prognostic marker research. This evolved to incorporate a comprehensive portfolio of immunological reagents used by scientists probing the underlying mechanisms common to many forms of cancer. GeneTex’s catalog has since expanded to offer a broad and diverse selection of antibody products covering a full range of research areas. GeneTex is proud to offer the highest quality antibody reagents supported by extensive research, development, and validation. We are committed to the highest standards of product performance.
51 to 200 staff
Abnova
Abnova is the first biotech company successfully integrated the IT-style management and industrial-scale antibody manufacturing. Our goal is to have at least one antibody to every human expressed gene in human genome. In Phase I of our business plans, we vastly expand the scope and availability of antibody reagents for the research market by taking a genome-wide approach to the high throughput production of human protein and antibody. There products are marketed through a combination of E-commerce based direct sales and a multi-tiered, sales network of over 49 distributors around the world. Starting from Year 2009 to 2013, in Phase II of the business plans, we have diversified into the systems arena focusing on antibody pairs, ELISA kits and instrumentation for rare cell isolation. In Phase we focus on in vitro diagnostics development concentrating on non-invasive, liquid biopsies of circulating tumor cells, ctDNA, and exosomes for precision medicine. Now in Phase IV (Year 2017 and later), we have focused on drug development specializing on immunotherapy. The value-added business has set the path of company's future growth and provided opportunity for Abnova to contribute to the biotech industry at large. We welcome researchers, biotech, and pharmaceutical companies to work with us and succeed together!
51 to 200 staff
Lumosa Therapeutics Co., Ltd
Lumosa Therapeutics, a public traded company in Taipei Exchange (6535.TWO), is dedicated to the development of innovative new drugs for the treatment of neurological and oncological diseases of unmet medical needs. The company is actively engaged in scientific in-licensing and new drug development under the “reSEARCH and DEVELOPMENT” model. This model is executed by a highly capable and experienced cross-functional teams of translational research, CMC, preclinical, clinical development, project management, regulatory affairs, intellectual property and business development experts. Current products/pipeline include Naldebain®, a long long-acting analgesic injection, launched in Taiwan in 2017, Singapore in 2020, Thailand in 2021, Malaysia in 2022, and Ukraine and Brunei in 2023; LT3001, an NCE for the treatment of acute ischemic stroke currently under phase II clinical trial in the US, EU, China and Taiwan; LT2003, tumor-targeting enzyme prodrug; LT5001, a novel topical drug for uremic pruritus; and LT6001, a novel exosome for treating nerve damages. The photo of Chingshui Cliff is used for the home page. The coastal cliff, located in Taroko National Park, averages 800 meters above sea level. The geo-formation of the cliff involves three continental plates: the Eurasian Plate, the Philippine Sea Plate, and the Pacific Plate. The collision of these three plates is what has led to the formation of the cliff. The sudden rise and majestic scene of the Chingshui Cliff represent our company's strive to achieve excellence and stand out in our industry.
11 to 50 staff
Plexbio Co., Ltd
PlexBio Co, Ltd, established in May 2010 to designs, develops and manufactures of IVD products and instrumentations in ISO-certified facilities. To this date, PlexBio has expanded from its headquarters in Taipei, Taiwan to Jiangsu Province, China and has an Innovative Technology Center in San Francisco, USA. Currently, PlexBio is a listed company at Taiwan emerging stock market. In order to address the issue of rising healthcare costs and an increasing range of available tests, it is crucial for clinical and research labs to consider the cost of labor, sample volume, time and maintenance when it comes to assay formats. Therefore, PlexBio aims to provide a cutting-edge multiplexing platform using patented Precision Image Code (π Code) MicroDisc technology to overcome this limitation. Our π Code Microdisc technology is currently the largest multiplexing platform, capable of generating around circular image patterns. Each image pattern corresponds to an individual target and can be detected simultaneously via advanced optical imaging and fluorescence analyzers. By using our multiplexing platform, we are able to offer highly sensitive and specific results with low sample volumes, which save time and labor. Currently, PlexBio is researching and developing high-quality reagents focusing on companion diagnostics, early cancer detection, prenatal diagnostics and food safety testing with ultra-detection sensitivity and fully automated diagnostics instruments for high-throughput clinical needs. With our innovative technologies, PlexBio intends to revolutionize the IVD industry developments, placing PlexBio as the leading brand of global IVD market.
51 to 200 staff
Syncell Inc
Syncell is a life sciences company focused on high-precision proteomic discovery. Its proprietary Microscoop® Mint platform delivers unmatched in situ proteome coverage and precision, surpassing the limits of traditional protein analysis approaches. Seamlessly compatible with mass spectrometry, the platform eliminates reliance on predefined targets, enabling a hypothesis-free workflow that is accelerating breakthroughs in diagnostic and therapeutic development, cell biology, neuroscience, oncology, immunology, spatial biology, and beyond. Syncell serves a growing global customer base with offices and laboratories in Livermore, Calif, and Taipei, Taiwan.
51 to 200 staff
Corum Inc
Established in 1987, Corum develops, manufactures and markets innovative active ingredients for the cosmetic and personal care industry. Our unique product portfolio consists of anti-ageing peptides, whitening vitamin C derivatives, specialty ingredients (heating/cooling agents), anti-acne active, glutamate surfactants, and moisturizing esters. The products are sustained by on-going research and clinical testing, as well as, highest standard in quality process control and services. Since Corum has been expanding its business globally: our items are promoted through distributors in more than 40 countries. Innovation, scientific rigor and quality assurance are the foundation of Corum’s business. These pillars drive the continual and thorough updating of the company’s know-how platforms, molecular cosmetics and biotechnology, and allow Corum to develop active ingredients as well as new cosmetic applications in a sustainable way. Working together, we always wish to bring success to our customers.
51 to 200 staff
Obi Pharma
OBI Pharma Inc.(OBI) is a global clinical stage oncology company that is headquartered in Taiwan. The company also has subsidiaries in the United States and Australia. It was founded in 2002 by Dr. Michael Chang, an accomplished biotech entrepreneur in the United States. Its stocks were issued publicly in 2012. Subsequently, the company was successfully listed on the Taipei Exchange (4174.TWO) in 2015. OBI focuses on innovative research and development for cancer therapies and aims to develop “first-in-class” and “best-in-class” ground-breaking drugs. It aspires to market these drugs worldwide with a “Made in Taiwan” branding and to provide new treatment options for patients with unmet medical needs. The core value of OBI lies in its passion to develop and deliver a portfolio of unique antibody-drug conjugates (ADC) drugs for patients, in addition to its promising Globo series (e.g, Globo H) of cancer therapeutic vaccines. This evolving portfolio includes a spectrum of cancer targets, such as TROP2, Nectin4, HER2, etc. These ADCs are built based on two distinct ADC technology platforms, each with different characteristics. Both platforms are customizable and offer a “plug-and-play” advantage through a specialized site-specific conjugation using a proprietary enzyme. With the added value of scalability, these “plug-and-play” technology platforms enable ADC development to be relatively simple and efficient. OBI is interested in commercializing its ADC technology platforms and looks forward to collaborating with biotech and pharmaceutical companies by enabling “first-in-class” and “best-in-class” therapeutic candidates for further development.
51 to 200 staff
Adimmune Corp 4142
Adimmune Corp (4142) is a biotechnology company based out of Taichung City, Taiwan.
501 to 1000 staff
Mackay Memorial Hospital
MACKAY MEMORIAL HOSPITAL is a biotechnology company based out of 92, Zhongshan N. Rd, Sec. 2, Taipei City, Taipei, Taiwan.
1001 to 5000 staff
Aixmed, Inc
Uncovering Cytology Insights in Seconds
11 to 50 staff
Oneness Biotech Co Ltd
Oneness Biotech is dedicated to fulfilling unmet medical needs by developing new drugs focused on chronic disorders in dermatology and immunology
51 to 200 staff
Tanbead Taiwan Advanced Nanotech Inc
Established in 2004, Taiwan Advanced Nanotech Inc.(TANBead) designs and manufactures products for nucleic acid purification, including reagent kits, magnetic nanoparticles, and automated extraction instruments. Our patented magnetic bead stirring technology empowers enhanced extraction efficiency. Each Maelstrom product embodies this novel technology and delivers improved performance for applications in molecular diagnostics and life sciences. Maelstrom products are FDA and CE approved, and the patents are granted in the EU, USA, Canada, Korea, Japan, China, and Taiwan. TANBead is a total solution provider for nucleic acid extraction.
201 to 500 staff
Tci Group
TCI is a leading bio-tech company in Taiwan, adopting the concept of Integrated Bioscience Design (IBD) to serve our clients. We manufacture high-performance products, such as nutrient foods (i.e, functional drinks, jellies, powders, tablets and capsules) and skin care products (i.e, biocellulose facial masks and essence concentrates). So far, our products have been sold to 66 countries in the world. With our outstanding research results, we were featured in the Discovery Exclusive Interview. Our Main Products / Service TCI’s concept of Integrated Bioscience Design (IBD) is inspired by consumer demand where we integrate professional multi-disciplinary knowledge and technology. They include: Chemistry, biology, mathematics, industrial engineering, genetic aesthetics, human factor engineering, applied materials and science and consumer behavior. We study and explore consumer needs in anti-aging, vivo environmental protection, postpartum care and male health from the market, and we endeavor accordingly to develop innovative products to improve consumer’s life. Employee Benefits We offer competitive salary based on the qualifications and experience employee’s competency. Furthermore, we take pride in offering a comprehensive and competitive benefits package as follows: Bonuses: year-end bonuses, performance bonuses, bonuses for special contributions Insurance Benefits: labor health insurance, travel insurance and those as required by laws Recreational Benefits: society activities, company trips, birthday parties and Christmas party, department dinners Other Benefits: TCI MVP, TCI coins, Oneiromancy plans
1001 to 5000 staff
Acepodia
Acepodia is a clinical-stage biotechnology company developing innovative and highly effective cell therapies for cancer that are broadly accessible for patients. Leveraging its Antibody-Cell Conjugation (ACC) technology, the company links tumor-targeting antibodies to its proprietary immune effector cells, such as gamma delta T cells and natural killer (NK) cells to create novel antibody cell effector (ACE) therapies, which have increased binding strength against tumors that express low levels of tumor antigens. Acepodia is made up of seasoned leadership and scientific experts dedicated to advancing its robust pipeline of off-the-shelf ACE therapies with the potential to bring powerful, accessible cell therapies to a broad population of patients across a variety of solid tumors and hematologic cancers.
51 to 200 staff
Medigen Biotechnology Corp
Medigen Biotechnology Corp. was established in late Our philosophy is “compassion, integrity, innovation and professionalism”. As a starting point, we consider the well-being of humanity, insisting that we take responsibility for guarding human life and health with a constant endeavor to fight for quality and dignity. We aim to see life blossom for ourselves and for others. For 15 years, Medigen has been constantly strengthening its research and development capability, hardware equipment, and technical ability. We do this in order to undertake the responsibilities independently in the field of molecular diagnostics, clinical trials, product regulation, and certification, medication manufacture with PIC/S standard, and regional marketing ability. Now, Medigen is a comprehensive biopharmaceutical corporation including; Medigen Biotechnology Corporation, Medigen Vaccine Biologics Corporation, TBG Incorporation, and Winston Biopharm Corporation. Medigen upholds the vision of “Innovations for a better life.” We believe that through cooperation and integration to reinforce international competitiveness, Medigen will become one of the most important players in the pharma biotechnology industry not only in Asia, but worldwide.
51 to 200 staff
Medigen Vaccine Biologics Corp
Established in 2012, Medigen Vaccine Biologics Corp (MVC) is a subsidiary of Medigen Biotechnology Corp Taipei, Taiwan. MVC develops vaccines and biosimilars for important unmet medical needs. Our focus is to deliver affordable medicines for developing countries and with a particular focus on SE Asia. We aim to become one of the leading pharmaceutical companies for Taiwan and global communities. Humanity, innovation, and quality are MVC core values. We integrate biomedical technologies to improve human health so that every person, from infants to seniors, has a chance to be free from infectious diseases. Our most advanced products are MVC-1901 and MVC-EVA71. MVC-1901 is a spike-protein-based subunit vaccine for COVID-19. Based on a very large phase 2 trial powered to assess safety and efficacy by immunobridging, the vaccine has EUA status in Taiwan. Phase 3 trials for full approval are in progress. MVC-EVC71A is an inactivated whole virus-based vaccine for enteroviral disease in children between 2 months and 12 years of age. The vaccine has recently completed a phase 3 trial and is currently in regulatory review for commercial licensing.
51 to 200 staff
Ok Biotech Co., Ltd
OK Biotech Co, Ltd. is one of the leading blood glucose device manufacturer in Taiwan. With the combined extraordinary R&D and world-class manufacturing capabilities, we dedicate ourselves to deliver the best valued products and the highest quality services to ensure your satisfaction. Currently, we are in the status of pre-IPO and is expected to IPO very soon. We are still expanding and looking for worldwide distributors for our OKmeter blood glucose device and medical products. With your channel expertise and our manufacturing competency, we believe OK Biotech and you could develop a mutual beneficial partnership.
51 to 200 staff
Steminent Biotherapeutics
Steminent Biotherapeutics Inc. is the leading stem cell clinical development company in Taipei, with subsidiaries in San Diego and Shanghai, dedicated to the development of novel cellular therapeutics for the treatment of diseases with unmet or under-served medical needs. Steminent utilizes advanced, proprietary processes and know how to isolate, purify, amplify and manufacture standardized stem cell products of the highest quality for research and clinical development in multiple indications. Steminent’s Stemchymal® allogeneic cell therapy R&D program has generated a portfolio of clinical stage therapeutic candidates for multiple diseases including: Phase II; Spinocerebellar Ataxia (PolyQ SCA), Phase I; Osteoarthritis of the Knee, and Phase I: Acute Liver Failure. Stemchymal® Stemchymal® 20162018714729710
51 to 200 staff
Acrocyte Therapeutics
AcroCyte Therapeutics is closing the gap between laboratory models and patient-specific medicine. Our core technology, the R³CE® platform, is an easy-to-use, FDA-designated Class I, scaffold-free system that rapidly expands minimal patient specimens—like circulating tumor cells, needle biopsies and frozen tissues—into functional 3D organoids in days. This breakthrough powers our commercial Onco-REAL™ clinical service, which provides comprehensive functional analysis from liquid biopsies for timely oncology decisions, while our autologous cell therapy pipeline aims to transform a patient’s own cells into curative solutions. We empower academic, clinical, and industry partners worldwide to leverage the R³CE® platform for novel drug discovery, diagnostics, and regenerative medicine, providing a foundational technology limited only by imagination. AcroCyte is driving a revolution to make these advanced platforms a routine part of clinical practice—accessible, affordable, and impactful for patients worldwide.
11 to 50 staff
Hanson Hong Biomedical Co., Ltd
We are a biotech manufacturer to produce three major product line. Customize autologous P-stem cell. Wound healing and medical aesthetic products and skincare products 3. diagnostic reagent - advance glycosylation end products test (AGEs test) for diabetic complication screening and monitor.
11 to 50 staff
Genereach Biotechnology Corporation
GRBC is committed to premium quality products and technical support for viral diagnosis.
51 to 200 staff
Instant Nanobiosensors
Instant NanoBiosensors (INB) is an innovative life sciences company that has developed next generation, ultra-sensitive digital immunoassay platforms that advance precision health for life sciences research and diagnostics. Our platform, Light Sensing Biomarker Analyzer, based on patented FOPPR (Fiber Optic Particle Plasmon Resonance) and IN-Chip (auto-flowing microfluidic chip) technologies with 35+ global patents for the life science research and in vitro diagnostics markets enables customers to reliably detect protein biomarkers in extremely low concentrations in blood, serum and other fluids that, in many cases, are undetectable using conventional, analog immunoassay technologies, and also allows researchers to define and validate the function of novel protein biomarkers that are only present in very low concentrations and have been discovered using technologies such as mass spectrometry.
11 to 50 staff
Neoasia Limited
NeoAsia Limited is the largest medical aesthetic group in Taiwan. Since 1993, NeoAsia Limited has grown rapidly to 130 employees managing distribution and manufacturing of cosmeceuticals and GMP-certified biomedical supplies. NeoAsia Limited is a major distributor of medical devices from the world's leading suppliers and manufacturers. The largest medical aesthetics training auditorium in Asia is located on the ground floor of NeoAsia Limited's Taipei headquarters. Training hundreds of doctors each year on the latest technologies and procedures in the medical cosmetic industry, doctors from Asia, Europe and North America attend these seminars in order to learn about the latest technological devices and procedures in the medical cosmetic industry. Experts in the Prolotherapy Treatment field including Dr. Standly Lam from Hong Kong, Dr. John Lyftoght from New Zealand and Dr. Lenny Horwitz from the U.S, annually attend major training courses related to their fields in order to act as guest speakers and trainers.
51 to 200 staff
Arce Therapeutics
ARCE Therapeutics, a Taiwan based biotech company, specializes in developing proprietary gene-modified cellular immunotherapies. ARCE’s CAR-T/NK cell therapy products are developed via three technologies, DashCAR®, MaxCAR®, and OneCAR®, for CAR immune cell therapy with high efficacy, safety, and durability, and thus to achieve a sustained improved response capable of conquering human diseases.
11 to 50 staff
